Lead Sponsor

AbbVie

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Have a physician-confirmed diagnosis of BP-I, with or without comorbidities.
•Prescribed cariprazine as part of routine clinical practice with the intention of treating as per the approved market label, respective country indications, and by the physician under usual and customary practice of physician prescription.
•Have a Montgomery-Åsberg Depression Rating Scale (MADRS) score \>= 20 at baseline.
•Have a Functioning Assessment Short Test (FAST) score \>= 21 at baseline.
•Naïve to cariprazine in the current major depressive episode.

•Have a medical or psychiatric condition, or planned surgical procedure, which will interfere with study participation, as judged by the investigator.
•Have a known contraindication to cariprazine including any of the following:
•* Hypersensitivity to cariprazine or any ingredient in the formulation
•* For all sites, concomitant use of strong cytochrome P450 (CYP) 3A4 inhibitors and inducers
•* For Canadian sites, as per country label, concomitant use of moderate CYP 3A4 inhibitors and inducers
•Current major depressive episode duration \> 12 months.

Related studies

NCT05837104 · Bipolar I Disorder, Depression, Anxiety, and more

NCT07540338 · Bipolar I Disorder

NCT07494305 · Bipolar I Disorder

NCT07172516 · Bipolar Disorder, Bipolar Depression, and more

NCT07288320 · Bipolar I Disorder, Mania

Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder